세계의 분자진단 시장 예측(-2029년) : 시장 규모, 점유율, 동향 : 제품·서비스별, 검사 유형별, 표본별, 기술별, 용도별

Molecular Diagnostics Market Size, Share & Trends by Product & Services, Test Type, Sample, Technology, Application (Infectious, Oncology) - Global Forecast to 2029

US $ 4,950 ￦ 6,986,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,386,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,503,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 14,115,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 분자진단 시장 규모는 2024년에 추정 173억 달러로, 2029년까지 327억 달러에 달할 것으로 예측되며, CAGR로 13.5%의 성장이 전망됩니다.

분자진단은 유전자 및 분자 에서 질병을 검사하여 질병을 조기에 발견할 수 있는 강력한 툴입니다. 이러한 첨단 기술을 통해 병원균을 민감하고 정확하게 찾아낼 수 있습니다. 조기 진단은 치료 시작을 앞당기고, 질병의 확산을 방지하고, 합병증을 줄이고, 환자의 전반적인 건강 상태를 개선할 수 있으므로 매우 중요합니다. 또한 인도와 같은 국가에서는 정부와 민간의 노력이 대중의 인식을 높이고 진단 및 치료 서비스에 대한 접근성을 보장하는 데 중요한 역할을 하고 있습니다. 이러한 노력으로 인해 향후 수년간 분자진단의 활용도가 높아질 것으로 예상됩니다.

조사 범위
조사 대상년	2022-2029년
기준년	2023년
예측 기간	2024-2029년
단위	금액
부문	제품·서비스별, 검사 유형별, 표본 유형별, 기술별, 용도별, 최종사용자별
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카, GCC 국가

"기술별로는 예측 기간에 DNA 시퀀싱·차세대 시퀀싱(NGS) 부문이 시장에서 가장 높은 성장률을 차지합니다."

시장의 DNA 시퀀싱·NGS 부문은 대폭적인 성장을 보이고 있습니다. 이 기술은 빠르게 발전하고 있으며, 더 빠르고, 더 정확하고, 더 저렴하게 DNA 염기서열을 결정할 수 있게 되었습니다. 고속 시퀀서, DNA 시료 처리 및 데이터 분석을 위한 더 나은 방법론과 같은 발전은 이러한 기술을 더욱 쉽고 효과적으로 사용할 수 있도록 하고 있습니다.

"최종사용자별로는 진단 실험실 부문이 예측 기간 중 시장에서 가장 빠른 성장률을 보일 것으로 예상됩니다."

진단 실험실 부문은 예측 기간 중 가장 높은 CAGR을 나타낼 것으로 예상됩니다. 이러한 성장은 효율적이고 정확한 솔루션을 필요로 하는 감염 및 암 검사 증가, 의료 인프라에 대한 투자 증가, 복잡한 분자 검사에 필요한 전문 지식의 존재로 인해 의료 서비스 프로바이더가 이러한 절차를 진단 실험실에 위탁하고 있기 때문인 것으로 추정됩니다.

"아시아태평양: 분자진단 시장에서 가장 빠르게 성장하는 지역"

특히 아시아태평양이 예측 기간 중 가장 큰 성장을 보일 것으로 예상됩니다. 의료관광의 중심지인 아시아태평양은 의료 시술 및 의료기기 시장의 선두주자로 빠르게 부상하고 있습니다. 또한 아시아태평양의 의료비 지출은 증가 추세에 있으며, 이는 고급 의료 서비스에 대한 수요가 증가하고 있음을 보여줍니다. 이러한 수요는 의료 인프라의 급속한 확장을 통해 충족되고 있으며, 특히 인도와 중국과 같은 국가에서는 병원과 진단 실험실이 크게 증가하고 있습니다. 또한 인도, 중국, 일본과 같은 국가들은 혁신적인 진단 방법 개발에 특화된 연구에 많은 투자를 하고 있습니다. 이러한 복합적인 요인들이 아시아태평양의 분자진단 시장을 촉진하고 있습니다.

세계의 분자진단 시장에 대해 조사분석했으며, 주요 촉진요인과 억제요인, 경쟁 구도, 향후 동향 등의 정보를 제공하고 있습니다.

목차

제1장 서론

제2장 조사 방법

제3장 개요

제4장 프리미엄 인사이트

• 분자진단 시장의 개요
• 분자진단 시장 : 제품·서비스별(2024년·2029년)
• 분자진단 시장 : 검사 유형별(2024년·2029년)
• 분자진단 시장 : 표본 유형별(2024년·2029년)
• 분자진단 시장 : 기술별(2024년·2029년)
• 분자진단 시장 : 용도별(2024년·2029년)
• 분자진단 시장 : 최종사용자별(2024년·2029년)
• 분자진단 시장 : 지역 목표 성장 기회

제5장 시장의 개요

• 서론
• 시장 역학
  • 촉진요인
  • 억제요인
  • 기회
  • 과제
• 가격 분석
  • 참고 가격 분석
  • 평균 판매 가격 : 지역별
• 특허 분석
• 밸류체인 분석
• 공급망 분석
• 무역 분석
• 에코시스템 분석
• Porter's Five Forces 분석
• 규제 상황
  • 규제기관, 정부기관, 기타 조직
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동
  • 아프리카
• 기술 분석
  • 주요 기술
  • 보완 기술
  • 인접 기술
• 주요 컨퍼런스와 이벤트(2024-2025년)
• 고객 비지니스에 영향을 미치는 동향/혼란
• 주요 이해관계자와 구입 기준
• 투자와 자금조달 시나리오
• 사례 연구 분석
• 분자진단 시장에 대한 AI의 영향

제6장 분자진단 시장 : 제품·서비스별

• 서론
• 시약·키트
• 기구
• 서비스·소프트웨어

제7장 분자진단 시장 : 검사 유형별

• 서론
• 임상 검사
• POC 검사

제8장 분자진단 시장 : 표본 유형별

• 서론
• 혈액, 혈청, 혈장
• 뇨
• 기타 표본 유형

제9장 분자진단 시장 : 기술별

• 서론
• 주요 산업 인사이트
• 중합효소 연쇄 반응
• 등온핵산증폭기술
• DNA 시퀀싱·차세대 시퀀싱
• In situ 하이브리다이제이션
• DNA 마이크로어레이
• 기타 기술

제10장 분자진단 시장 : 용도별

• 서론
• 감염증 진단
  • 간염
  • HIV
  • CT/NG
  • HAI
  • HPV
  • 결핵
  • 인플루엔자
  • 기타 감염증
• 종양 검사
  • 유방암
  • 대장암
  • 폐암
  • 전립선암
  • 기타 암 유형
• 유전자 검사
• 기타 용도

제11장 분자진단 시장 : 최종사용자별

• 서론
• 진단 검사실
• 병원·진료소
• 기타 최종사용자

제12장 분자진단 시장 : 지역별

• 서론
• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 러시아
  • 스위스
  • 기타 유럽
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
• 중동 및 아프리카
• GCC 국가

제13장 경쟁 구도

• 서론
• 주요 기업 전략/유력 기업
• 매출 분석
• 시장 점유율 분석
• 기업 평가 매트릭스 : 주요 기업(2023년)
• 기업 평가 매트릭스 : 스타트업/중소기업(2023년)
• 기업 평가와 재무 지표
• 브랜드/제품 비교
  • DANAHER
  • F. HOFFMANN-LA ROCHE LTD.
  • ABBOTT
• 경쟁 시나리오

제14장 기업 개요

• 주요 기업
  • DANAHER
  • F. HOFFMANN-LA ROCHE LTD.
  • ILLUMINA, INC.
  • HOLOGIC, INC.
  • BIOMERIEUX
  • ABBOTT
  • THERMO FISHER SCIENTIFIC INC.
  • QIAGEN
  • REVVITY
  • MYRIAD GENETICS, INC.
  • SIEMENS HEALTHINEERS AG
• 기타 기업
  • BECTON, DICKINSON AND COMPANY
  • GRIFOLS, S.A.
  • QUIDELORTHO CORPORATION
  • DIASORIN S.P.A.
  • EXACT SCIENCES CORPORATION
  • GENETIC SIGNATURES
  • AGILENT TECHNOLOGIES, INC.
  • MDXHEALTH
  • BIOCARTIS
  • TBG DIAGNOSTICS LIMITED
  • HTG MOLECULAR DIAGNOSTICS, INC.
  • VELA DIAGNOSTICS
  • AMOY DIAGNOSTICS CO., LTD.
  • ELITECHGROUP
  • MOLBIO DIAGNOSTICS PVT. LTD.
  • GENEOMBIO TECHNOLOGIES
  • SAVYON DIAGNOSTICS
  • UNIOGEN OY

제15장 부록

KSA

영문 목차

영문목차

The molecular diagnostics market is valued at an estimated USD 17.3 billion in 2024 and is projected to reach USD 32.7 billion by 2029 at a CAGR of 13.5% during the forecast period. Molecular diagnostics is a powerful tool for detecting diseases early by examining them at the genetic and molecular level. These advanced techniques can find pathogens very precisely and with high sensitivity. Early diagnosis is crucial because it lets treatment begin sooner, which can prevent the spread of the disease, lessen complications, and improve overall patient health. Moreover, in countries like India, both government and private initiatives are playing a significant role in enhancing public awareness and ensuring greater accessibility to diagnostic and treatment services. Such initiatives are expected to increase the use of molecular diagnostics in the coming years.

Scope of the Report
Years Considered for the Study	2022-2029
Base Year	2023
Forecast Period	2024-2029
Units Considered	Value (USD Billion)
Segments	By Product & service, test type, sample type, technology, application, and end user
Regions covered	North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries

"DNA sequencing & next-generation sequencing (NGS) segment accounted for the highest growth rate in the molecular diagnostics market, by technology, during the forecast period."

Based on technology, the molecular diagnostics market is bifurcated into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies. The DNA sequencing & NGS segment in the molecular diagnostics market is experiencing substantial growth. This technology has been rapidly improving, with faster, more accurate, and more affordable ways to sequence DNA. Advancements like high-speed sequencers and better methods for processing DNA samples and data analysis are making these technologies easier to use and more effective.

"Diagnostic laboratories segment is expected to have the fastest growth rate in the molecular diagnostics market, by end user, during the forecast period."

The molecular diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, and other end users, based on end user. Diagnostic laboratories segment is expected to account for the highest CAGR during the forecast period. This growth can be attributed to factors like the increasing volume of tests for infectious diseases and cancer that necessitates efficient and accurate solutions, increasing investments in healthcare infrastructure, and the presence of the specialized expertise required for complex molecular testing that are prompting healthcare providers to outsource these procedures to diagnostic laboratories.

"Asia Pacific: The fastest-growing region in molecular diagnostics market."

The worldwide market for molecular diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. Notably, the Asia Pacific region is anticipated to experience the most substantial growth in the forecast period. The Asia Pacific region, a hub for medical tourism, is rapidly emerging as a leader in the market for medical procedures and devices. Furthermore, healthcare spending in Asia Pacific is on the rise, indicating a growing demand for advanced medical services. This demand is being met by the rapid expansion of medical infrastructure, particularly in countries like India and China, where the number of hospitals and diagnostic laboratories is experiencing significant growth. Additionally, countries like India, China, and Japan are making substantial investments in research dedicated to developing innovative diagnostic procedures. This confluence of factors is propelling the molecular diagnostics market within the Asia Pacific region.

The break-up of the profile of primary participants in the molecular diagnostics market:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in this market are Danaher (US), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (US), bioMerieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Myriad Genetics, Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Exact Sciences Corporation (US), Genetic Signatures (Australia), Agilent Technologies, Inc. (US), MDxHealth (Belgium), Biocartis (Belgium), TBG Diagnostics Limited (Australia), HTG Molecular Diagnostics, Inc. (US), Vela Diagnostics (Singapore), Amoy Diagnostics Co., Ltd. (China), ELITechGroup (France), Molbio Diagnostics Pvt. Ltd. (India), geneOmbio Technologies (India), Savyon Diagnostics (Israel), and Uniogen OY (Finland).

Research Coverage:

This research report categorizes the molecular diagnostics market by product & service (reagents & kits, instruments, and services), by test type (lab tests and PoC tests), by sample type (blood, serum & plasma, urine, and other sample types, by technology (polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies, by application (infectious disease diagnostics (hepatitis [hepatitis B, hepatitis C & other hepatitis diseases], HIV, CT/NG, HAI, HPV, tuberculosis, influenza, and other infectious diseases), oncology testing (breast cancer, colorectal cancer, lung cancer, prostate cancer, and other cancers), genetic testing and other applications), by end user (hospitals& clinics, diagnostic laboratories, and other end users), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the molecular diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the molecular diagnostics market. Competitive analysis of upcoming startups in the molecular diagnostics market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall molecular diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Increasing prevalence of infectious diseases and cancer globally, rising focus on R&D and growing funding in molecular diagnostics by healthcare-based companies, growing awareness regarding early disease diagnosis in developing countries, rising technological advancements in molecular diagnostics in recent years, and increasing use of PoC diagnostic tests in homecare settings and hospitals), opportunities (Growing significance of companion diagnostics in drug development process and increasing growth opportunities for molecular diagnostics companies in emerging economies), restraints (Unfavorable reimbursement scenario for diagnostic companies and high cost of molecular diagnostic instruments), and challenges (Changing regulatory landscape for IVD and molecular diagnostics in US and European Union, operational barriers and shortage of skills across major markets, and introduction of alternative technologies for disease detection and diagnosis) influencing the growth of the molecular diagnostics market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular diagnostics market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the molecular diagnostics market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular diagnostics market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Illumina, Inc. (US), bioMerieux (France), and Hologic, Inc. (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 LIMITATIONS
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Primary interview participants
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Approach 1: Company revenue estimation approach
    • 2.3.1.2 Approach 2: Presentation of companies and primary interviews
    • 2.3.1.3 Approach 3: Estimation of total molecular-based test for HIV in US
    • 2.3.1.4 Growth forecast
    • 2.3.1.5 CAGR projections
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 MARKET SHARE ANALYSIS
• 2.6 RESEARCH ASSUMPTIONS
  • 2.6.1 PARAMETRIC ASSUMPTIONS
  • 2.6.2 GROWTH RATE ASSUMPTIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW
• 4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029
• 4.3 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2024 VS. 2029
• 4.4 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024 VS. 2029
• 4.5 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029
• 4.6 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2024 VS. 2029
• 4.7 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029
• 4.8 MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing prevalence of infectious diseases and cancer
    • 5.2.1.2 Growing R&D funding
    • 5.2.1.3 Surge in technological advancements
    • 5.2.1.4 Rising use of point-of-care diagnostic tests
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Inadequate reimbursements
    • 5.2.2.2 High cost of molecular diagnostic instruments
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing significance of companion diagnostics
    • 5.2.3.2 Increasing growth opportunities in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Changing regulatory landscape
    • 5.2.4.2 Operational barriers and labor shortage
    • 5.2.4.3 Introduction of alternative technologies
• 5.3 PRICING ANALYSIS
  • 5.3.1 INDICATIVE PRICING ANALYSIS
  • 5.3.2 AVERAGE SELLING PRICE, BY REGION
• 5.4 PATENT ANALYSIS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 TRADE ANALYSIS
• 5.8 ECOSYSTEM ANALYSIS
  • 5.8.1 MOLECULAR DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF BUYERS
  • 5.9.4 BARGAINING POWER OF SUPPLIERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.2 NORTH AMERICA
    • 5.10.2.1 US
    • 5.10.2.2 Canada
  • 5.10.3 EUROPE
  • 5.10.4 ASIA PACIFIC
    • 5.10.4.1 China
    • 5.10.4.2 Japan
    • 5.10.4.3 India
  • 5.10.5 LATIN AMERICA
    • 5.10.5.1 Brazil
    • 5.10.5.2 Mexico
  • 5.10.6 MIDDLE EAST
  • 5.10.7 AFRICA
• 5.11 TECHNOLOGY ANALYSIS
  • 5.11.1 KEY TECHNOLOGY
    • 5.11.1.1 Polymerase chain reaction
  • 5.11.2 COMPLEMENTARY TECHNOLOGY
    • 5.11.2.1 Microarrays
  • 5.11.3 ADJACENT TECHNOLOGY
    • 5.11.3.1 Next-generation sequencing
• 5.12 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 INVESTMENT AND FUNDING SCENARIO
• 5.16 CASE STUDY ANALYSIS
• 5.17 IMPACT OF ARTIFICIAL INTELLIGENCE ON MOLECULAR DIAGNOSTICS MARKET

6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 REAGENTS & KITS
  • 6.2.1 INCREASING AWARENESS ABOUT EARLY DISEASE DETECTION AND PREVENTIVE HEALTHCARE TO PROPEL MARKET
• 6.3 INSTRUMENTS
  • 6.3.1 RISING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST MARKET
• 6.4 SERVICES & SOFTWARE
  • 6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE MARKET

7 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE

• 7.1 INTRODUCTION
  • 7.1.1 KEY INDUSTRY INSIGHTS
• 7.2 LAB TESTS
  • 7.2.1 INCREASING NEED FOR AUTOMATION AND EFFICIENT DISEASE TESTING TO DRIVE MARKET
• 7.3 POC TESTS
  • 7.3.1 GROWING INVESTMENTS FROM PUBLIC HEALTH AGENCIES AND GOVERNMENT TO BOOST MARKET

8 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE

• 8.1 INTRODUCTION
• 8.2 BLOOD, SERUM, AND PLASMA
  • 8.2.1 INCREASING UTILIZATION IN GENETIC TESTING, INFECTIOUS DISEASE DIAGNOSIS, AND CANCER DIAGNOSTICS TO PROPEL MARKET
• 8.3 URINE
  • 8.3.1 NEED FOR NON-INVASIVE AND EASY SAMPLE COLLECTION TECHNIQUE TO FUEL MARKET
• 8.4 OTHER SAMPLE TYPES

9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY

• 9.1 INTRODUCTION
• 9.2 KEY INDUSTRY INSIGHTS
• 9.3 POLYMERASE CHAIN REACTION
  • 9.3.1 RISING USE IN PROTEOMICS AND GENOMICS TO AID GROWTH
• 9.4 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
  • 9.4.1 NEED TO DEVELOP ANTIRETROVIRAL DRUGS AND PROMPT DIAGNOSIS TO STIMULATE GROWTH
• 9.5 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
  • 9.5.1 GROWING SHIFT TOWARD MOLECULAR-TARGETED DRUGS AND THERAPIES TO DRIVE MARKET
• 9.6 IN SITU HYBRIDIZATION
  • 9.6.1 RISING APPLICATIONS IN DIAGNOSING CHROMOSOMAL ABNORMALITIES, GENE MAPPING, AND INFERTILITY TREATMENT TO BOOST MARKET
• 9.7 DNA MICROARRAYS
  • 9.7.1 SURGE IN ADVANCEMENTS IN DESIGN, DENSITY, AND DETECTION TECHNIQUES TO FUEL MARKET
• 9.8 OTHER TECHNOLOGIES

10 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

• 10.1 INTRODUCTION
• 10.2 INFECTIOUS DISEASE DIAGNOSTICS
  • 10.2.1 HEPATITIS
    • 10.2.1.1 Hepatitis B
      • 10.2.1.1.1 Need for ongoing management and monitoring of virus to drive market
    • 10.2.1.2 Hepatitis C
      • 10.2.1.2.1 Favorable government initiatives to support growth
    • 10.2.1.3 Other hepatitis diseases
  • 10.2.2 HIV
    • 10.2.2.1 Increasing blood transfusions and blood donations to propel market
  • 10.2.3 CT/NG
    • 10.2.3.1 Growing development of novel assays to boost market
  • 10.2.4 HAI
    • 10.2.4.1 Booming geriatric population to aid growth
  • 10.2.5 HPV
    • 10.2.5.1 Rising cases of cervical cancer to augment growth
  • 10.2.6 TUBERCULOSIS
    • 10.2.6.1 Rising focus on reducing tuberculosis deaths to fuel market
  • 10.2.7 INFLUENZA
    • 10.2.7.1 Growing strains and subtypes to drive market
  • 10.2.8 OTHER INFECTIOUS DISEASES
• 10.3 ONCOLOGY TESTING
  • 10.3.1 BREAST CANCER
    • 10.3.1.1 Increasing need to improve survival rates to support growth
  • 10.3.2 COLORECTAL CANCER
    • 10.3.2.1 Rising demand for biomarkers to fuel market
  • 10.3.3 LUNG CANCER
    • 10.3.3.1 Increasing use of predictive biomarkers to drive market
  • 10.3.4 PROSTATE CANCER
    • 10.3.4.1 Surge in advancements in genomic technologies to aid growth
  • 10.3.5 OTHER CANCER TYPES
• 10.4 GENETIC TESTING
  • 10.4.1 GROWING IMPORTANCE IN DIAGNOSING AND MANAGING RARE GENETIC DISEASES TO PROPEL MARKET
• 10.5 OTHER APPLICATIONS

11 MOLECULAR DIAGNOSTICS MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 DIAGNOSTIC LABORATORIES
  • 11.2.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR COST REDUCTION TO AID GROWTH
• 11.3 HOSPITALS & CLINICS
  • 11.3.1 GROWING FOCUS ON HEALTHCARE SYSTEMS TO STIMULATE GROWTH
• 11.4 OTHER END USERS

12 MOLECULAR DIAGNOSTICS MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 US
    • 12.2.1.1 Presence of advanced healthcare infrastructure and high healthcare expenditures to drive market
  • 12.2.2 CANADA
    • 12.2.2.1 Growing focus on genomic research to fuel market
• 12.3 EUROPE
  • 12.3.1 GERMANY
    • 12.3.1.1 Robust healthcare spending and increasing per capita disposable income to propel market
  • 12.3.2 UK
    • 12.3.2.1 Increasing number of accredited clinical laboratories and hospital laboratories to fuel market
  • 12.3.3 FRANCE
    • 12.3.3.1 Rising R&D expenditure for product launches and development of new technologies to augment market
  • 12.3.4 ITALY
    • 12.3.4.1 Growing demographic shift toward elderly population to support market
  • 12.3.5 SPAIN
    • 12.3.5.1 Surge in demand for genetic and prenatal testing to aid growth
  • 12.3.6 RUSSIA
    • 12.3.6.1 Increasing access to quality healthcare to boost market
  • 12.3.7 SWITZERLAND
    • 12.3.7.1 Rising healthcare spending for new medications and therapies to drive market
  • 12.3.8 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 CHINA
    • 12.4.1.1 Rapid economic growth to drive market
  • 12.4.2 JAPAN
    • 12.4.2.1 Universal healthcare reimbursement policy to support market
  • 12.4.3 INDIA
    • 12.4.3.1 Increasing penetration of medical insurance, hospital setups, and foreign direct investments to fuel market
  • 12.4.4 AUSTRALIA
    • 12.4.4.1 Rising technological advancements and automation to stimulate growth
  • 12.4.5 SOUTH KOREA
    • 12.4.5.1 Favorable government initiatives for promoting medical tourism to support growth
  • 12.4.6 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 BRAZIL
    • 12.5.1.1 Need for accurate and detailed disease profiling to drive market
  • 12.5.2 MEXICO
    • 12.5.2.1 Booming medical tourism industry to aid growth
  • 12.5.3 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 GROWING INVESTMENTS IN HEALTHCARE PROJECTS TO PROPEL MARKET
• 12.7 GCC COUNTRIES
  • 12.7.1 RISING FOCUS ON ADVANCED HEALTH INFRASTRUCTURE TO DRIVE MARKET

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
• 13.3 REVENUE ANALYSIS
• 13.4 MARKET SHARE ANALYSIS
  • 13.4.1 MOLECULAR DIAGNOSTICS MARKET RANKING ANALYSIS, BY TECHNOLOGY
    • 13.4.1.1 Polymerase chain reaction
    • 13.4.1.2 DNA sequencing and next-generation sequencing
    • 13.4.1.3 Isothermal nucleic acid amplification technology
    • 13.4.1.4 In situ hybridization
  • 13.4.2 MOLECULAR DIAGNOSTICS MARKET RANKING ANALYSIS, BY APPLICATION
    • 13.4.2.1 Infectious disease diagnostics
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT, KEY PLAYERS, 2023
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Product footprint
    • 13.5.5.3 Application footprint
    • 13.5.5.4 Region footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 13.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 13.7.1 FINANCIAL METRICS
  • 13.7.2 COMPANY VALUATION
• 13.8 BRAND/PRODUCT COMPARISON
  • 13.8.1 DANAHER
  • 13.8.2 F. HOFFMANN-LA ROCHE LTD.
  • 13.8.3 ABBOTT
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT LAUNCHES
  • 13.9.2 DEALS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 DANAHER
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product launches and approvals
      • 14.1.1.3.2 Deals
      • 14.1.1.3.3 Expansions
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Right to win
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses and competitive threats
  • 14.1.2 F. HOFFMANN-LA ROCHE LTD.
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product launches and approvals
      • 14.1.2.3.2 Deals
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Right to win
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 ILLUMINA, INC.
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches and approvals
      • 14.1.3.3.2 Deals
      • 14.1.3.3.3 Expansions
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Right to win
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 HOLOGIC, INC.
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches and approvals
      • 14.1.4.3.2 Deals
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Right to win
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses and competitive threats
  • 14.1.5 BIOMERIEUX
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches and approvals
      • 14.1.5.3.2 Deals
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Right to win
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 ABBOTT
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches and approvals
  • 14.1.7 THERMO FISHER SCIENTIFIC INC.
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Product launches and approvals
      • 14.1.7.3.2 Deals
  • 14.1.8 QIAGEN
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Product launches and approvals
      • 14.1.8.3.2 Deals
      • 14.1.8.3.3 Expansions
  • 14.1.9 REVVITY
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
  • 14.1.10 MYRIAD GENETICS, INC.
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Product launches and approvals
  • 14.1.11 SIEMENS HEALTHINEERS AG
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Product launches and approvals
      • 14.1.11.3.2 Deals
      • 14.1.11.3.3 Expansions
• 14.2 OTHER PLAYERS
  • 14.2.1 BECTON, DICKINSON AND COMPANY
  • 14.2.2 GRIFOLS, S.A.
  • 14.2.3 QUIDELORTHO CORPORATION
  • 14.2.4 DIASORIN S.P.A.
  • 14.2.5 EXACT SCIENCES CORPORATION
  • 14.2.6 GENETIC SIGNATURES
  • 14.2.7 AGILENT TECHNOLOGIES, INC.
  • 14.2.8 MDXHEALTH
  • 14.2.9 BIOCARTIS
  • 14.2.10 TBG DIAGNOSTICS LIMITED
  • 14.2.11 HTG MOLECULAR DIAGNOSTICS, INC.
  • 14.2.12 VELA DIAGNOSTICS
  • 14.2.13 AMOY DIAGNOSTICS CO., LTD.
  • 14.2.14 ELITECHGROUP
  • 14.2.15 MOLBIO DIAGNOSTICS PVT. LTD.
  • 14.2.16 GENEOMBIO TECHNOLOGIES
  • 14.2.17 SAVYON DIAGNOSTICS
  • 14.2.18 UNIOGEN OY

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS

관련자료